Siglec-3

Gene Synonyms:

Protein Names:

Organism:

Homo sapiens (Human)

Mass (kDa):

39825

Length (aa):

364

Sequence:

MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGKQETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTHPTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNPSKDTSTEYSEVRTQ

Proteomics (Proteome ID):

Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33)

Proteomics (Chromosome):

UP000005640

Mass Spectrometry:

N/A

Function [CC]:

Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in maintaining immune cells in a resting state (PubMed:10611343, PubMed:15597323, PubMed:11320212). Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans (PubMed:7718872). Upon engagement of ligands such as C1q or syalylated glycoproteins, two immunoreceptor tyrosine-based inhibitory motifs (ITIMs) located in CD33 cytoplasmic tail are phosphorylated by Src-like kinases such as LCK (PubMed:28325905, PubMed:10887109). These phosphorylations provide docking sites for the recruitment and activation of protein-tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2 (PubMed:10556798, PubMed:10206955, PubMed:10887109). In turn, these phosphatases regulate downstream pathways through dephosphorylation of signaling molecules (PubMed:10206955, PubMed:10887109). One of the repressive effect of CD33 on monocyte activation requires phosphoinositide 3-kinase/PI3K (PubMed:15597323). {ECO:0000269|PubMed:10206955, ECO:0000269|PubMed:10556798, ECO:0000269|PubMed:10611343, ECO:0000269|PubMed:10887109, ECO:0000269|PubMed:11320212, ECO:0000269|PubMed:15597323, ECO:0000269|PubMed:28325905, ECO:0000269|PubMed:7718872}.

Metal Binding:

N/A

Site:

N/A

Tissue Specificity:

Monocytic/myeloid lineage cells. In the brain, CD33 is mainly expressed on microglial cells.

Disease:

N/A

Mutagenesis:

MUTAGEN 100 100 N->A: Significant loss of binding to peripheral blood granulocytes. {ECO:0000269|PubMed:8702538}.; MUTAGEN 340 340 Y->A: Abolishes binding to PTPN6 and PTPN11. Increases binding of red blood cells. {ECO:0000269|PubMed:10206955}.; MUTAGEN 340 340 Y->F: Complete loss of phosphorylation by LCK. {ECO:0000269|PubMed:10887109}.; MUTAGEN 358 358 Y->A,F: Reduces binding to PTPN6. {ECO:0000269|PubMed:10556798}.; MUTAGEN 358 358 Y->F: More than 50% loss of phosphorylation by LCK. {ECO:0000269|PubMed:10887109}.

Name:

Myeloid cell surface antigen CD33 (Sialic acid-binding Ig-like lectin 3) (Siglec-3) (gp67) (CD antigen CD33)

Class:

Subcategory:

Recombinant

Source:

Species:

Human

Amino Acid Sequence:

Tag:

Format:

Lyophilized

Formulation:

Sterile-filtered colorless solution

Formulation Concentration:

1mg/ml

Buffer Volume:

Standard

Buffer Solution:

PBS

pH:

7.4-7.5

NaCl:

Null

EDTA:

Null

Purity:

> 98%

Determined:

SDS-PAGE

Stained:

Inquire

Validated:

RP-HPLC

Storage:

-20°C

Stability:

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Preparation:

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.